STOCK TITAN

TRACON Pharmaceuticals Inc - TCON STOCK NEWS

Welcome to our dedicated news page for TRACON Pharmaceuticals (Ticker: TCON), a resource for investors and traders seeking the latest updates and insights on TRACON Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TRACON Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TRACON Pharmaceuticals's position in the market.

Rhea-AI Summary
TRACON Pharmaceuticals announces financial results for Q2 2023, including the collection of a $22M arbitration award. The company expects the award to extend its cash runway into early 2024. Interim efficacy assessment for ENVASARC trial expected later this quarter. Envafolimab shows a double-digit objective response rate (ORR) and is well tolerated. Upcoming milestones include completing accrual of the ENVASARC trial in Q4 2023 and final data from the trial in mid-2024. Cash position of $1.9 million at June 30, 2023, expected to fund the company into Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
-
Rhea-AI Summary
TRACON Pharmaceuticals, Inc. (Nasdaq: TCON) will report its Q2 2023 financial and operating results on August 14, 2023, followed by a conference call to discuss the results and corporate activities. The company utilizes a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and partner with other life science companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
conferences earnings
-
Rhea-AI Summary
TRACON Pharmaceuticals collects arbitration award from I-Mab Biopharma, extending cash runway into early 2024 and past expected full accrual of the ENVASARC pivotal trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
none
Rhea-AI Summary
TRACON Pharmaceuticals announced positive results of a six-month independent data monitoring committee (IDMC) review for the ongoing ENVASARC Phase 2 pivotal trial. The review showed that single agent envafolimab achieved a double-digit objective response rate (ORR) without any > Grade 2 drug-related toxicity. The combination of envafolimab with Yervoy did not demonstrate synergy, leading to termination of enrollment in cohort D. Enrollment in the separate trial of TRACON's CTLA-4 antibody YH001 with envafolimab and doxorubicin will continue. The company expects to report trial data at the Connective Tissue Oncology Society (CTOS) annual meeting in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.35%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
Rhea-AI Summary
TRACON Pharmaceuticals announces financial results for Q1 2023 and provides corporate updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.2%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
TRACON Pharmaceuticals Inc

Nasdaq:TCON

TCON Rankings

TCON Stock Data

5.37M
2.08M
2.6%
11.66%
1.64%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
San Diego

About TCON

tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w